Abstract Details
|
Tiago Mestre, MD, MSC
(University of Ottawa)
PRESENTER |
Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CHDI. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ipsen. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Mestre has received research support from CIHR. The institution of Dr. Mestre has received research support from Ontario Research Fund. The institution of Dr. Mestre has received research support from MJFF. The institution of Dr. Mestre has received research support from Parkinson Canada. The institution of Dr. Mestre has received research support from University of Ottawa/PRC. |
| Cheryl Fitzer-Attas, PhD (ClinMed LLC) | Dr. Fitzer-Attas has received personal compensation for serving as an employee of Sage Therapeutics. The institution of Dr. Fitzer-Attas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pharma Two B. The institution of Dr. Fitzer-Attas has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Golden Heart Flower. The institution of Dr. Fitzer-Attas has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Sage Therapeutics. Dr. Fitzer-Attas has stock in Golden Heart Flower. Dr. Fitzer-Attas has received intellectual property interests from a discovery or technology relating to health care. |
| No disclosure on file | |
| Bernhard G. Landwehrmeyer, MD (Ulm University Hospital) | Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ACADIA PHARMACEUTICALS INC, San Diego, CA. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck Valby, Denmark. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AOP Orphan Pharmaceuticals AG, Vienna, Austria. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Remix Therapeutics, Inc., Cambridge, MA. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for HSG Clinical Research, Inc. Dr. Landwehrmeyer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for F. Hoffmann-La Roche Ltd, Basel, Switzerland. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Pharma AG, Grenzach/Whylen, Germany. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis Pharma AG, Basel, Switzerland. The institution of Dr. Landwehrmeyer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis Pharma AG, Basel, Switzerland. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics, Inc., South Plainfield, NJ . Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Triplet Therapeutics, Inc. Cambridge, MA. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda Pharma. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche Pharma AG, Grenzach/Whylen, Germany. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for F. Hoffmann-La Roche Ltd, Basel, Switzerland. Dr. Landwehrmeyer has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis Pharma AG, Basel, Switzerland. The institution of Dr. Landwehrmeyer has received research support from CHDI Foundation. The institution of Dr. Landwehrmeyer has received research support from European Commission. The institution of Dr. Landwehrmeyer has received research support from German Federal Government BMBF. The institution of Dr. Landwehrmeyer has received research support from German Research Council DFG. Dr. Landwehrmeyer has received publishing royalties from a publication relating to health care. Dr. Landwehrmeyer has received publishing royalties from a publication relating to health care. |
| Cristina Sampaio, Prof (CHDI) | No disclosure on file |